MannKind Corporation (NASDAQ:MNKD) can breathe a little easier now that the U.S. Food and Drug Administration (FDA) has approved the drug Afrezza to the general market on Tuesday, which may have saved the company from sinking. MannKind Corporation (NASDAQ:MNKD) shares after opening at $7.75 moved to $8.08 on last trade day and at the end of the day closed at $6.99. Company price to cash ratio as 37.24. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 20.52%.
Neuralstem, Inc. (NYSEMKT:CUR) on Mar. 28 announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem’s NSI-566 stem cells in the brain experienced functional improvements. Neuralstem, Inc. (NYSEMKT:CUR) shares advanced 4.48% in last trading session and ended the day on $4.43. Neuralstem, Inc. (NYSEMKT:CUR) return on equity ratio is recorded as -303.90% and its return on assets is -135.00%. Neuralstem, Inc. (NYSEMKT:CUR) yearly performance is 310.19%.
On March 26, 2014, Franklin M. Berger, currently a member of the Board of Directors (the “Board”) of Seattle Genetics, Inc. (NASDAQ:SGEN), notified the Company of his resignation from the Board. Seattle Genetics, Inc. (NASDAQ:SGEN) shares moved down -6.16% in last trading session and was closed at $43.91, while trading in range of $43.76 – $47.39. Seattle Genetics, Inc. (NASDAQ:SGEN) year to date (YTD) performance is 10.08%.
Wedbush initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $10.00 price target on the stock. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) weekly performance is -11.02%. On last trading day company shares ended up $11.30. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) distance from 50-day simple moving average (SMA50) is -16.70%. Analysts mean target price for the company is $19.78.
Leave a Reply